![Wioleta Zelek](https://profiles-cardiff.imgix.net/attachments/2652?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Wioleta Zelek
(she/her)
- Available for postgraduate supervision
Teams and roles for Wioleta Zelek
Senior Research Fellow, UK-DRI Emerging Leader, RAD & ARUK Fellow
Overview
I have a strong research focus on the complement system, its biology, and its roles in disease, as well as strategies to manipulate the system for therapy. My work includes developing a toolbox of complement inhibitors, including antibodies and small molecules, that target different complement pathways and are cross-reactive with humans and rodents. To measure complement dysregulation precisely, I have developed assays and antibodies that enable accurate detection and quantification, supporting biomarker discovery and translational research.
https://www.raceagainstdementia.com/rad-fellows/dr-wioleta-zelek/
https://ukdri.ac.uk/team/wioleta-zelek
Publication
2025
- Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
- Chen, D. et al., 2025. Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI. Blood 146 (6), pp.759-764. (10.1182/blood.2024028012)
- Cooke, R. S. et al. 2025. CD59, disulphide‐locked human C9 and horse C9 inhibit human membrane attack complex assembly by similar mechanisms. Immunology (10.1111/imm.70008)
- Daskoulidou, N. et al. 2025. The Alzheimer's disease‐associated complement receptor 1 variant confers risk by impacting glial phagocytosis. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 (7) e70458. (10.1002/alz.70458)
- Li, Y. et al., 2025. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Science Advances 11 (28) eadw1731. (10.1126/sciadv.adw1731)
- Nguyen, V. D. et al. 2025. Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus.. [Online].bioRxiv: openRxiv. (10.1101/2025.05.06.652374)Available at: https://doi.org/10.1101/2025.05.06.652374.
- Reed, R. M. et al., 2025. Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men. Endocrinology and Metabolism 328 (4), pp.e611-e619. (10.1152/ajpendo.00419.2024)
- Smith-Jackson, K. et al., 2025. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International 107 (4), pp.700-713. (10.1016/j.kint.2024.12.016)
- Zelek, W. M. et al. 2025. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain 148 (3), pp.941-954. (10.1093/brain/awae278)
- Zelek, W. M. et al. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20 (S6)(10.1002/alz.090708)
- Zelek, W. M. and Tenner, A. J. 2025. Complement therapeutics in neurodegenerative diseases. Immunobiology 230 (4) 153089. (10.1016/j.imbio.2025.153089)
2024
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5 (3), pp.239-253. (10.1016/j.medj.2024.01.011)
- Daskoulidou, N. et al. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al., Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg. , pp.1-22. (10.1007/7854_2024_524)
- Kharnaf, M. et al., 2024. Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.. The Journal of Thoracic and Cardiovascular Surgery 168 (2), pp.E37-E53. (10.1016/j.jtcvs.2023.08.045)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Nimmo, J. et al. 2024. The complement system in neurodegenerative diseases. Clinical Science 138 (6), pp.387-412. (10.1042/cs20230513)
- Zelek, W. M. 2024. Is Long COVID a complement dysregulation disease?. Clinical Chemistry (10.1093/clinchem/hvae088)
- Zelek, W. M. , Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118 , pp.355-363. (10.1016/j.bbi.2024.03.017)
2023
- Goff, L. M. et al., 2023. Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity. Clinical & Experimental Immunology 212 (1)(10.1093/cei/uxad011)
- Kamegai, N. et al., 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214 (2), pp.209-218. (10.1093/cei/uxad088)
- Siggins, M. K. et al., 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168 (3), pp.473-492. (10.1111/imm.13585)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19 (4), pp.1383-1392. (10.1002/alz.12799)
- Veteleanu, A. et al., 2023. Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation 20 (1) 169. (10.1186/s12974-023-02850-6)
- Zelek, W. M. and Harrison, R. A. 2023. Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know. Immunobiology 228 (3) 152393. (10.1016/j.imbio.2023.152393)
2022
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Kolka, C. M. et al., 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13 842023. (10.3389/fimmu.2022.842023)
- Lekova, E. et al., 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 968206. (10.3389/fimmu.2022.968206)
- Lewis, L. A. et al., 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10), pp.1861–1864. (10.1093/infdis/jiab630)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43 (8), pp.615-628. (10.1016/j.tips.2022.02.006)
2021
- Mc Mahon, O. et al., 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30 (13), pp.1188-1199. (10.1093/hmg/ddab086)
- Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16 (1) e0245382. (10.1371/journal.pone.0245382)
- Syrimi, E. et al., 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) 103215. (10.1016/j.isci.2021.103215)
- Webster, J. A. et al., 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13 (12) 2865. (10.3390/cancers13122865)
- Zelek, W. 2021. Measuring total classical pathway and activities of individual components of the mouse complement pathway. Bio-protocol 11 (19) e4175. (10.21769/BioProtoc.4175)
2020
- Buckland, M. S. et al., 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11 (1) 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M. et al. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161 (2), pp.103-113. Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11 (11) 612402. (10.3389/fimmu.2020.612402)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
2019
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204 , pp.16-22. (10.1016/j.schres.2017.12.012)
- Zelek, W. 2019. Targeting the terminal pathway in complement – driven disease.. PhD Thesis , Cardiff University.
- Zelek, W. M. , Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157 (4), pp.283-295. (10.1111/imm.13083)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Zelek, W. M. et al. 2019. Compendium of current complement therapeutics. Molecular Immunology 114 , pp.341-352. (10.1016/j.molimm.2019.07.030)
2018
- Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Zelek, W. M. , Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223 (12), pp.744-749. (10.1016/j.imbio.2018.07.016)
- Zelek, W. M. et al. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155 (3), pp.396-403. (10.1111/imm.12982)
Articles
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5 (3), pp.239-253. (10.1016/j.medj.2024.01.011)
- Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)
- Buckland, M. S. et al., 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11 (1) 6385. (10.1038/s41467-020-19761-2)
- Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
- Chen, D. et al., 2025. Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI. Blood 146 (6), pp.759-764. (10.1182/blood.2024028012)
- Cooke, R. S. et al. 2025. CD59, disulphide‐locked human C9 and horse C9 inhibit human membrane attack complex assembly by similar mechanisms. Immunology (10.1111/imm.70008)
- Daskoulidou, N. et al. 2025. The Alzheimer's disease‐associated complement receptor 1 variant confers risk by impacting glial phagocytosis. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 21 (7) e70458. (10.1002/alz.70458)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Goff, L. M. et al., 2023. Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity. Clinical & Experimental Immunology 212 (1)(10.1093/cei/uxad011)
- Kamegai, N. et al., 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214 (2), pp.209-218. (10.1093/cei/uxad088)
- Kharnaf, M. et al., 2024. Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.. The Journal of Thoracic and Cardiovascular Surgery 168 (2), pp.E37-E53. (10.1016/j.jtcvs.2023.08.045)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Kolka, C. M. et al., 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13 842023. (10.3389/fimmu.2022.842023)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204 , pp.16-22. (10.1016/j.schres.2017.12.012)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp.1-7. (10.1016/j.seizure.2018.05.016)
- Lekova, E. et al., 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13 968206. (10.3389/fimmu.2022.968206)
- Lewis, L. A. et al., 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225 (10), pp.1861–1864. (10.1093/infdis/jiab630)
- Li, Y. et al., 2025. Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors. Science Advances 11 (28) eadw1731. (10.1126/sciadv.adw1731)
- Mc Mahon, O. et al., 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30 (13), pp.1188-1199. (10.1093/hmg/ddab086)
- Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16 (1) e0245382. (10.1371/journal.pone.0245382)
- Nimmo, J. et al. 2024. The complement system in neurodegenerative diseases. Clinical Science 138 (6), pp.387-412. (10.1042/cs20230513)
- Reed, R. M. et al., 2025. Plasma complement system markers and their association with cardiometabolic risk factors: an ethnic comparison of White European and Black African men. Endocrinology and Metabolism 328 (4), pp.e611-e619. (10.1152/ajpendo.00419.2024)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Siggins, M. K. et al., 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168 (3), pp.473-492. (10.1111/imm.13585)
- Smith-Jackson, K. et al., 2025. The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome. Kidney International 107 (4), pp.700-713. (10.1016/j.kint.2024.12.016)
- Syrimi, E. et al., 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) 103215. (10.1016/j.isci.2021.103215)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19 (4), pp.1383-1392. (10.1002/alz.12799)
- Veteleanu, A. et al., 2023. Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation 20 (1) 169. (10.1186/s12974-023-02850-6)
- Webster, J. A. et al., 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13 (12) 2865. (10.3390/cancers13122865)
- Zelek, W. 2021. Measuring total classical pathway and activities of individual components of the mouse complement pathway. Bio-protocol 11 (19) e4175. (10.21769/BioProtoc.4175)
- Zelek, W. M. 2024. Is Long COVID a complement dysregulation disease?. Clinical Chemistry (10.1093/clinchem/hvae088)
- Zelek, W. M. , Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118 , pp.355-363. (10.1016/j.bbi.2024.03.017)
- Zelek, W. M. et al. 2025. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain 148 (3), pp.941-954. (10.1093/brain/awae278)
- Zelek, W. M. et al. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20 (S6)(10.1002/alz.090708)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M. , Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223 (12), pp.744-749. (10.1016/j.imbio.2018.07.016)
- Zelek, W. M. and Harrison, R. A. 2023. Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know. Immunobiology 228 (3) 152393. (10.1016/j.imbio.2023.152393)
- Zelek, W. M. et al. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161 (2), pp.103-113. Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11 (11) 612402. (10.3389/fimmu.2020.612402)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43 (8), pp.615-628. (10.1016/j.tips.2022.02.006)
- Zelek, W. M. et al. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155 (3), pp.396-403. (10.1111/imm.12982)
- Zelek, W. M. , Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157 (4), pp.283-295. (10.1111/imm.13083)
- Zelek, W. M. and Tenner, A. J. 2025. Complement therapeutics in neurodegenerative diseases. Immunobiology 230 (4) 153089. (10.1016/j.imbio.2025.153089)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
- Zelek, W. M. et al. 2019. Compendium of current complement therapeutics. Molecular Immunology 114 , pp.341-352. (10.1016/j.molimm.2019.07.030)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
Book sections
- Daskoulidou, N. et al. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al., Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg. , pp.1-22. (10.1007/7854_2024_524)
Thesis
- Zelek, W. 2019. Targeting the terminal pathway in complement – driven disease.. PhD Thesis , Cardiff University.
Websites
- Nguyen, V. D. et al. 2025. Complement biosynthesis in human brain: Insights from single-nucleus transcriptomics of hippocampus.. [Online].bioRxiv: openRxiv. (10.1101/2025.05.06.652374)Available at: https://doi.org/10.1101/2025.05.06.652374.
Research
My current focus is on generating anti-complement drugs for treatment of common inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, kidneys disorders and dementia. During the pandemic I have re-focussed my work to address relevant issues; I supported a compassionate use study of anti-complement therapy in severe Covid-19, and developed assays for measurement of antibodies against the RBD domain of the SARS-Cov2 virus.
Grants and awards:
Jan 2022 – present: RAD/ARUK Fellow & UK-DRI Emerging Leader.
"Targeting novel anti-complement drugs to the brain for therapy of dementia."
https://ukdri.ac.uk/team/wioleta-zelek
Oct 2020 - Dec 2021: HCRW Fellow.
"Drug design for specific inhibition of the Membrane Attack Complex (MAC) in common inflammatory diseases."
Oct 2019 - Sep 2020: ISSF Fellow.
"Structure-function guided drug design for specific inhibition of the Membrane Attack Complex (MAC) in complement driven diseases."
Oct 2016 - Sep 2019: PhD Student.
"Targeting the terminal pathway in complement – driven disease."
Biography
Jan 2022 – present: Cardiff University, School of Medicine, Dementia Research Institute, Research Fellow. Race Against Dementia / Alzheimer's Research UK Fellowship Award & UK-DRI Emerging Leader status. "Targeting novel anti-complement drugs to the brain for therapy of dementia."
Oct 2020 – Dec 2021: Cardiff University, School of Medicine, Research Associate. Health and Care Research Fellowship Award. "Drug design for specific inhibition of the Membrane Attack Complex (MAC) in common inflammatory diseases."
Oct 2019 – Sep 2020: Cardiff University, School of Medicine, Research Associate. Institutional Strategic Support Fund via Wellcome Trust Consolidator Award. "Structure-function guided drug design for specific inhibition of the Membrane Attack Complex (MAC) in complement driven diseases."
Oct 2016 – Sep 2019: Cardiff University, School of Medicine, PhD Student. "Targeting the terminal pathway in complement - driven disease".
Jan 2015 – Sep 2016: Cardiff University, School of Medicine, Research Technician in Prof. B. Paul Morgan Group. "Complement biomarkers in autoimmune diseases."
Industry:
Jan 2013 – Dec 2014: RSR Limited, Cardiff. Scientist.
Jan 2007 – Dec 2013: BBI Group, Cardiff, Senior Scientist.
Dec 2006 – Dec 2007: Cardiff and Vale NHS Trust, Cardiff, Medical Laboratory Assistant.
Development of new products: ELISAs and LFAs; improvement of immunoassays performance and manufacturing processes, troubleshooting on products stability and sensitivity issues; data analysis of results obtained and generation of customer reports. Training and supervision of staff. Generation and approval of laboratory protocols; SOP's, EP's, QCP's, PP's. Accustomed to ISO 9001:2008, ISO13485:2003, FDA, GLP, GMP, PPE, SEQOHS, COSHH, H&S, GCP.
Supervisions
Current supervision
Rebekah Cooke
Contact Details
[email protected]
+44 29206 87860
Henry Wellcome Building for Biomedical Research, Floor 4th Floor, Room 4F10, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
+44 29206 87860
Henry Wellcome Building for Biomedical Research, Floor 4th Floor, Room 4F10, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
